Celldex Rose on Phase 2 Melanoma Data
On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.
Immunomedics Has Fallen More than 30% on January 18
On January 18, Immunomedics (IMMU) is trading close to $12.27, which is ~32.17% lower than its previous closing price.
Mirati Therapeutics Stock Has Delivered Solid Growth in 2018
On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.
Here’s What’s Driving Investor Interest in Immunomedics
Clinical stage biopharmaceutical company Immunomedics (IMMU) is currently focused on advancing several research programs.
Investors Not Impressed with Immunomedics’ IMMU-132 Study
On June 6, 2016, biotech stocks continued their upward trend and appeared to be in a positive, consolidating mood. IBB rose 1.5% that day.